By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said it’s with the University of Florida’s Center for Translational Research in Neurodegenerative Disease (CTRND) to develop vaccines for diseases like Alzheimer’s and Parkinson’s. The collaboration aims to understand and neutralize toxic brain proteins, Vaxxinity said. UF researchers will conduct preclinical studies to evaluate candidates and potentially offer […]
By Daniella Parra Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) said it showed additional safety and tolerability data, marking the second positive Phase 3 study assessing TNX-102 SL for fibromyalgia management. Tonix said the study met its primary endpoint, demonstrating statistically significant and clinically meaningful daily pain reduction over placebo. The results also revealed a favorable […]
By Daniella Parra Eterna Therapeutics Inc. (Nasdaq: ERNA) said it appointed Dr. James Bristol, an experienced biopharmaceutical executive with a background in research and drug discovery, to its Board of Directors. Before his retirement from Pfizer in 2007, Dr. Bristol held various key positions in research and drug discovery and was responsible for overseeing significant […]
By Daniella Parra Apollomics Inc. (Nasdaq: APLM) unveiled results from the KUNPENG clinical trial at ESMO 2023, showing vebreltinib’s potential as a treatment for cancers with MET alterations, they said. The Phase 2 trial by Apollomics’ partner, Avistone Biotechnology Ltd., demonstrated a 75% overall response rate in patients with advanced NSCLC, along with other positive […]
By Daniella Parra Sparrow Pharmaceuticals said it initiated a Phase 2 ACSpire study for SPI-62, a potent HSD-1 inhibitor, targeting autonomous cortisol secretion (ACS). ACS results from excessive cortisol production due to benign adrenal tumors and can lead to severe health issues. The company said that the study assesses SPI-62’s impact on ACS-related conditions, enrolling […]